|
| Study ID | Morbidity | 30-day mortality | Postoperative adjuvant therapy Rate | Median OS (m) | Median follow-up (m) | Non-liver resection treatments | Conclusion |
| Hepatic resection | Non-liver resection |
|
| Birnbaum 2015 | 44.00% | 5.00% | NR | 90 | NR | NR | Resection of primary tumors | Resection of liver metastases improve survival |
| Xu 2015 | NR | NR | NR | 57.2 | 54.8 | 32 | Somatostatin analogues and chemotherapy | Resection of liver metastases could not prolong OS but could improve PFS |
| Partelli 2015 | 44.44% | NR | 68.00% | 97 | 36 | 41 | Somatostatin analogues, PRRT, chemotherapy | Resection of liver metastases improve survival |
| Zerbi 2013 | NR | NR | 48.68% | NR | 20.5 | 21 | Somatostatin analogues, PRRT, ablation, chemotherapy | Resection of liver metastases could be the first-choice treatment for malignent PNET |
| Kleine 2011 | 22.22% | NR | NR | NR | 37.8 | 40 | Resection of primary tumors | Resection of liver metastases may prolong OS |
| Mayo 2011 | NR | NR | NR | 123 | 33 | 26 | Intra-arterial therapy and resection of primary tumors | Hepatectomy most benefited those patients with low-volume ( <25%) liver metastasis or those with symptomatic high-volume liver metastasis |
| House 2006 | 25.00% | 0.00% | 11.54% | 78 | 17 | NR | Somatostatin analogues, chemotherapy, chemoembolization and resection of primary tumors | There is a survival benefit from complete surgical resection of metastatic islet cell tumors originating from the pancreas |
| Osborne 2006 | 3.28% | 1.64% | 65.57% | NR | NR | NR | Somatostatin analogues and chemotherapy, PRRT, embolization | Patients who undergo surgical cytoreduction of symptomatic neuroendocrine hepatic metastases enjoy prolonged survival when compared with their medically treated counterparts |
| Musunuru 2006 | NR | NR | 8.00% | NR | NR | 20 | Systemic hormonal and chemotherapy, ablation, hepatic artery embolization | In patients with liver-only neuroendocrine metastases, surgical therapy is associated with improved survival |
| Touzios 2005 | 42.00% | 5.30% | 36.00% | >96 | NR | NR | Somatostatin analogues, chemotherapy, PRRT, ablation and resection of primary tumors | Resection has been shown to be an excellent treatment and accumulating data document improved survival with resection of these tumors |
| Solorzano2001 | NR | NR | 60.00% | 36 | 21.6 | 32 | Chemotherapy, hepatic artery embolization | Aggressive management should probably be restricted to younger patients with limited extrahepatic disease |
| Chamberlain 2000 | NR | NR | NR | NR | NR | 27 | Hepatic artery embolization, Somatostatin analogues and chemotherapy and resection of primary tumors | Hepatic resection has a role in the man-agement of patients with NET metastases and may prolong survival |
| Chen 1998 | NR | NR | 0.00% | NR | 27 | 27 | Chemoembolization, chemotherapy, PRRT and resection of primary tumors | Hepatic resection for metastatic neuroen-docrine tumors may prolong survival |
|
